Medpace Holdings, Inc. $MEDP Shares Purchased by GAMMA Investing LLC

GAMMA Investing LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 69.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 521 shares of the company’s stock after purchasing an additional 214 shares during the quarter. GAMMA Investing LLC’s holdings in Medpace were worth $164,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Medpace by 245.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,371 shares of the company’s stock valued at $2,781,000 after acquiring an additional 5,949 shares during the period. NBC Securities Inc. acquired a new position in shares of Medpace during the first quarter valued at $593,000. Merit Financial Group LLC boosted its holdings in shares of Medpace by 25.3% during the first quarter. Merit Financial Group LLC now owns 2,289 shares of the company’s stock valued at $697,000 after acquiring an additional 462 shares during the period. HBW Advisory Services LLC boosted its holdings in shares of Medpace by 10.7% during the first quarter. HBW Advisory Services LLC now owns 837 shares of the company’s stock valued at $255,000 after acquiring an additional 81 shares during the period. Finally, Portside Wealth Group LLC boosted its holdings in shares of Medpace by 14.6% during the first quarter. Portside Wealth Group LLC now owns 903 shares of the company’s stock valued at $300,000 after acquiring an additional 115 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Trading Up 0.8%

NASDAQ MEDP opened at $500.76 on Tuesday. The stock’s 50-day moving average price is $468.67 and its two-hundred day moving average price is $362.54. The company has a market cap of $14.07 billion, a PE ratio of 37.23, a PEG ratio of 3.13 and a beta of 1.44. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $506.55.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on MEDP shares. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and boosted their price target for the company from $300.00 to $305.00 in a report on Tuesday, July 29th. Robert W. Baird boosted their price target on shares of Medpace from $313.00 to $490.00 and gave the company a “neutral” rating in a report on Wednesday, July 23rd. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, September 22nd. Jefferies Financial Group upped their price objective on shares of Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Finally, Truist Financial upped their price objective on shares of Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Medpace has a consensus rating of “Reduce” and an average target price of $422.27.

Insider Activity

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares in the company, valued at approximately $2,725,380. The trade was a 66.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares in the company, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.